Analyst Suneet Kamath from Jefferies reiterated a Buy rating on Metlife (MET – Research Report) and keeping the price target at $104.00.
Suneet Kamath’s rating is based on MetLife’s performance and future outlook. The company showed a recovery in the fourth quarter of 2024, bouncing back from a weaker performance in the previous quarter. The results included a slight beat in operating earnings per share, which aligns with expectations for a continued positive growth trajectory. Despite some mixed projections for 2025, MetLife’s commitment to achieving double-digit EPS growth and a return on equity ranging between 15-17% reinforces confidence in its future performance.
Furthermore, specific segments like Group Benefits and Retirement & Income Solutions are expected to contribute positively, with growth in premiums and favorable loss ratios. While there are challenges such as foreign exchange impacts and certain underperforming regions, MetLife’s financial metrics remain stable, including its capital position and free cash flow conversion. These factors, along with the company’s strategic initiatives, underpin Kamath’s decision to maintain a Buy rating, reflecting an optimistic view of MetLife’s potential to deliver shareholder value.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $92.00 price target.
Based on the recent corporate insider activity of 113 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MET in relation to earlier this year.